Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF

Sponsor
University Hospital, Basel, Switzerland
Study ID
NCT01805960
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to test the efficacy of a single injection of Canakinumab on AF recurrences within 6 months after electrical cardioversion in patients with persistent AF.

Key Dates

Start date
Jun 30, 2013
Status verified
Feb 2017
Primary completion
Dec 31, 2016
Completion
Dec 31, 2016

Study Design

Enrollment
24 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Canakinumab
    1 s.c. injection of canakinumab 150mg directly after cardioversion
  • Placebo Comparator: Placebo
    1 s.c. injection directly after cardioversion

Primary Outcome Measure

Recurrence of atrial fibrillation [ Time Frame: 180 days ]

Related Studies